Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.
  • Unibest NewCo & Licensing Pipeline

    2025-08-29

    Current list of Unibest's innovative drug assets open for global licensing, co-developement and/or NewCo. Read More
  • Unibest FDF Pipeline

    2025-08-29

    Current list of finished dosage formulations open for global market distribution and technology transfer. Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Sep 08 2025

    2025-09-08

    This week, there are 6 drugs in the patent and exclusivity list. They are: - GERON CORP's RYTELO, containing active ingredient IMETELSTAT SODIUM - MYLAN SPECIALTY LP's EPIPEN JR., containing active ingredient EPINEPHRINE - MYLAN SPECIALTY LP's EPIPEN, containing active ingredient EPINEPHRINE - BAUSCH AND LOMB INC's PROLENSA, containing active ingredient BROMFENAC SODIUM - EISAI INC's HALAVEN, containing active ingredient ERIBULIN MESYLATE - MERIDIAN MEDICAL TECHNOLOGIES LLC's SEIZALAM, containing active ingredient MIDAZOLAM HYDROCHLORIDE Read More
  • Eli Lilly Announces Positive Results for Orforglipron in Phase 3 ATTAIN-2 Trial

    2025-09-02

    On August 26, 2025, Eli Lilly and Company announced that their small molecule GLP-1 receptor agonist, Orforglipron, achieved positive results in the third phase 3 clinical trial, ATTAIN-2. Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Sep 01 2025

    2025-09-01

    This week, there are 10 drugs in the patent and exclusivity list. They are: - SUCAMPO PHARMA AMERICAS LLC's AMITIZA, containing active ingredient LUBIPROSTONE - GENENTECH INC's ERIVEDGE, containing active ingredient VISMODEGIB - GE HEALTHCARE's VIZAMYL, containing active ingredient FLUTEMETAMOL F-18 - AVERITAS PHARMA INC's QUTENZA, containing active ingredient CAPSAICIN - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's PRADAXA, containing active ingredient DABIGATRAN ETEXILATE MESYLATE - BAYER HEALTHCARE PHARMACEUTICALS INC's KERENDIA, containing active ingredient FINERENONE - VERTEX PHARMACEUTICALS INC's ORKAMBI, containing active ingredient IVACAFTOR; LUMACAFTOR - CURIUM US LLC's DETECTNET, containing active ingredient COPPER CU-64 DOTATATE - RIGEL PHARMACEUTICALS INC's GAVRETO, containing active ingredient PRALSETINIB - ASTELLAS PHARMA US INC's CRESEMBA, containing active ingredient ISAVUCONAZONIUM SULFATE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Aug 25 2025

    2025-08-25

    This week, there are 5 drugs in the patent and exclusivity list. They are: - GALDERMA LABORATORIES LP's MIRVASO, containing active ingredient BRIMONIDINE TARTRATE - PF PRISM CV's XALKORI, containing active ingredient CRIZOTINIB - ALNYLAM PHARMACEUTICALS INC's GIVLAARI, containing active ingredient GIVOSIRAN SODIUM - INCYTE CORP's PEMAZYRE, containing active ingredient PEMIGATINIB - SUN PHARMACEUTICAL INDUSTRIES LTD's WINLEVI, containing active ingredient CLASCOTERONE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Aug 18 2025

    2025-08-18

    This week, there are 10 drugs in the patent and exclusivity list. They are: - SPRINGWORKS THERAPEUTICS INC's OGSIVEO, containing active ingredient NIROGACESTAT HYDROBROMIDE - VERO BIOTECH INC's GENOSYL, containing active ingredient NITRIC OXIDE - CURRAX PHARMACEUTICALS LLC's ONZETRA XSAIL, containing active ingredient SUMATRIPTAN SUCCINATE - SANDOZ INC's QOLIANA, containing active ingredient BRIMONIDINE TARTRATE - UNITED THERAPEUTICS CORP's TYVASO DPI, containing active ingredient TREPROSTINIL - CUMBERLAND PHARMACEUTICALS INC's ACETADOTE, containing active ingredient ACETYLCYSTEINE - AXSOME THERAPEUTICS INC's AUVELITY, containing active ingredient BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - BIOCODEX SA's DIACOMIT, containing active ingredient STIRIPENTOL - PHARMACYCLICS LLC's IMBRUVICA, containing active ingredient IBRUTINIB - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JARDIANCE, containing active ingredient EMPAGLIFLOZIN Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Aug 11 2025

    2025-08-11

    This week, there are 6 drugs in the patent and exclusivity list. They are: - NOVO NORDISK INC's OZEMPIC, containing active ingredient SEMAGLUTIDE - NOVO NORDISK INC's VICTOZA, containing active ingredient LIRAGLUTIDE - NOVO NORDISK INC's SAXENDA, containing active ingredient LIRAGLUTIDE - NIPPON SHINYAKU CO LTD's VILTEPSO, containing active ingredient VILTOLARSEN - VERTEX PHARMACEUTICALS INC's KALYDECO, containing active ingredient IVACAFTOR - EISAI INC's LENVIMA, containing active ingredient LENVATINIB MESYLATE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Aug 04 2025

    2025-08-04

    This week, there are 9 drugs in the patent and exclusivity list. They are: - BRISTOL MYERS SQUIBB CO's SPRYCEL, containing active ingredient DASATINIB - GILEAD SCIENCES INC's ZYDELIG, containing active ingredient IDELALISIB - SUMITOMO PHARMA SWITZERLAND GMBH's MYFEMBREE, containing active ingredient ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - BAYER HEALTHCARE PHARMACEUTICALS INC's NUBEQA, containing active ingredient DAROLUTAMIDE - BAYER HEALTHCARE PHARMACEUTICALS INC's LAMPIT, containing active ingredient NIFURTIMOX - VERTEX PHARMACEUTICALS INC's ORKAMBI, containing active ingredient IVACAFTOR; LUMACAFTOR - GENENTECH INC's EVRYSDI, containing active ingredient RISDIPLAM - ALNYLAM PHARMACEUTICALS INC's ONPATTRO, containing active ingredient PATISIRAN SODIUM - AMICUS THERAPEUTICS US LLC's GALAFOLD, containing active ingredient MIGALASTAT HYDROCHLORIDE Read More
  • Total 15 pages  Go to Page
  • Go